254 related articles for article (PubMed ID: 36065644)
21. Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia.
Nozaki S; Garg A; Vega GL; Grundy SM
Am J Clin Nutr; 1991 Mar; 53(3):638-42. PubMed ID: 2000816
[TBL] [Abstract][Full Text] [Related]
22. Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction.
Shaik A; Rosenson RS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):677-690. PubMed ID: 33710501
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the effect of post-heparin and pre-heparin lipoprotein lipase and hepatic triglyceride lipase on remnant lipoprotein metabolism.
Shirakawa T; Nakajima K; Shimomura Y; Kobayashi J; Stanhope K; Havel P; Machida T; Sumino H; Murakami M
Clin Chim Acta; 2015 Feb; 440():193-200. PubMed ID: 25239670
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
Kwiterovich PO
Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479
[TBL] [Abstract][Full Text] [Related]
25. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
Ganda OP; Bhatt DL; Mason RP; Miller M; Boden WE
J Am Coll Cardiol; 2018 Jul; 72(3):330-343. PubMed ID: 29935936
[TBL] [Abstract][Full Text] [Related]
26. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease.
Heo JH; Jo SH
J Korean Med Sci; 2023 Sep; 38(38):e295. PubMed ID: 37750369
[TBL] [Abstract][Full Text] [Related]
27. In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase.
Chung BH; Segrest JP; Franklin F
Atherosclerosis; 1998 Dec; 141(2):209-25. PubMed ID: 9862170
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
29. In vitro remodelling of plasma lipoproteins in whole plasma by lipoprotein lipase in primary and secondary hypertriglyceridaemia.
Levy E; Deckelbaum RJ; Thibault RL; Seidman E; Olivecrona T; Roy CC
Eur J Clin Invest; 1990 Aug; 20(4):422-31. PubMed ID: 2121502
[TBL] [Abstract][Full Text] [Related]
30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular disease and dyslipidemia: beyond LDL.
Pöss J; Custodis F; Werner C; Weingärtner O; Böhm M; Laufs U
Curr Pharm Des; 2011; 17(9):861-70. PubMed ID: 21418031
[TBL] [Abstract][Full Text] [Related]
32. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
Rosenson RS; Davidson MH; Hirsh BJ; Kathiresan S; Gaudet D
J Am Coll Cardiol; 2014 Dec; 64(23):2525-40. PubMed ID: 25500239
[TBL] [Abstract][Full Text] [Related]
33. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations.
Tory R; Sachs-Barrable K; Goshko CB; Hill JS; Wasan KM
Transplantation; 2009 Jul; 88(1):62-8. PubMed ID: 19584682
[TBL] [Abstract][Full Text] [Related]
35. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
36. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
Murdoch SJ; Breckenridge WC
Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of lipoprotein lipase in transgenic Watanabe heritable hyperlipidemic rabbits improves hyperlipidemia and obesity.
Koike T; Liang J; Wang X; Ichikawa T; Shiomi M; Liu G; Sun H; Kitajima S; Morimoto M; Watanabe T; Yamada N; Fan J
J Biol Chem; 2004 Feb; 279(9):7521-9. PubMed ID: 14660566
[TBL] [Abstract][Full Text] [Related]
38. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
Karpe F; Tornvall P; Olivecrona T; Steiner G; Carlson LA; Hamsten A
Atherosclerosis; 1993 Jan; 98(1):33-49. PubMed ID: 8457249
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of lipoprotein lipase induced cholesterol ester accumulation in human hepatoma HepG2 cells.
Cianflone K; Avramoglu RK; Sawyez C; Huff MW
Atherosclerosis; 1996 Feb; 120(1-2):101-14. PubMed ID: 8645351
[TBL] [Abstract][Full Text] [Related]
40. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
